Ask Us
Safety Alert: Ibandronate Sodium
Early communication of ongoing safety review
What does this mean?
The US FDA has issued an early communication about the ongoing review of new safety data for bisphosphanate medicines such as Ibandronate Sodium. The communication was issued by the FDA after it received reports of abnormal heart rhythms that may have been associated with bisphosphanate use.
Upon initial review, it is unclear how this data should be interpreted. Therefore, FDA does not believe that healthcare providers or patients should change either their prescribing practices or their use of bisphosphonates at this time.
The US FDA has issued an early communication about the ongoing review of new safety data for bisphosphanate medicines such as Ibandronate Sodium. The communication was issued by the FDA after it received reports of abnormal heart rhythms that may have been associated with bisphosphanate use.
Upon initial review, it is unclear how this data should be interpreted. Therefore, FDA does not believe that healthcare providers or patients should change either their prescribing practices or their use of bisphosphonates at this time.
For more information, please visit:
